Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia
Status:
Unknown status
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
The vast majority of patients with AML will die of the disease, and no standard chemotherapy
regimen were defined for patients with relapsed/refractory AML. Previous studies have
confirmed the efficacy of cladribine in the treatment of AML, both de novo or
relapse/refractory AML. Our previous experience has shown that Cladribine in combination of
CAG (G-CSF priming, low dose cytarabine, and aclarubicin) are effective with tolerable
toxicity profiling.Thus, this phase 2 clincial trial is going to evaluate the efficacy and
safety of cladribine in combination with G-CSF, low-dose cytarabine and aclarubicin (C-CAG)
in patients with refractory/relapsed acute myeloid leukemia.